US-based radiopharmaceutical company Lantheus has announced a definitive agreement to acquire clinical-stage radiopharma contract development and manufacturing organisation (CDMO) Evergreen ...

With the aim to add a “revenue generating CDMO arm,” Lantheus Holdings has bought New Jersey-based radiopharmaceutical company Evergreen Theragnostics.

The Bedford company announced its acquisition of Evergreen Theragnostics Inc. Tuesday. Lantheus (Nasdaq: LNTH) is paying $250 million upfront in the all-cash transaction, plus up to an additional ...

Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen Theragnostics for $250 million upfront. As part of the deal, which was announced ...

Lantheus will acquire Evergreen Theragnostics for $250 million upfront, plus up to $752.5 million in milestone payments, closing in H2 2025. The Life Molecular Imaging acquisition adds Neuraceq to ...

Lantheus and Evergreen expect the deal to close in the second quarter of 2025. The transaction will allow Lantheus to get its hands on Evergreen’s scalable radioligand therapy (RLT ...

Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment of $250M and up to an additional $752.5M in ...

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

On Tuesday, Lantheus Holdings, Inc. (NASDAQ:LNTH) agreed to acquire Evergreen Theragnostics, Inc. in an all-cash transaction involving an upfront payment of $250 million and up to an additional $ ...